EhmetDx revealed on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance for its 3D CBCT positioning software for patient treatment.
In December 2018, the 3D CBCT positioning system will be used to precisely guide the position of the proton beam in patient treatment at the McLaren Proton Therapy Centre.
With patient treatment imminent, the company's team will turn its efforts to focus on commercialisation of the Mammoknife: the world's first self-shielded, linac-based breast cancer radiotherapy device that will raise the standard of treatment for women globally, added its founder and CEO Michael Teicher.
Headquartered in Plymouth, Michigan, EhmetDx is commercialising the latest identifiable needs of the medical market. It is a consortium of health care focused engineers, scientists and executives from diverse backgrounds that have collaborated to bring a sense of integrity and execution to the device industry.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval